Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions
Resectable, Non-functioning Pituitary Adenoma
Interventions
DRUG

Farletuzumab

Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.

Trial Locations (1)

30322

Emory University, Atlanta

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Morphotek

INDUSTRY